Enter Discount Code 10HEALTHY at checkout for $10 off orders of $100 or more! Brand exclusions apply - Click for details
Healthy Habits Living is an authorized retailer of
Ortho Molecular
products.
Pre-Meal Appetite Management
Calocurb® CLINICAL is a practitioner-exclusive supplement that supports appetite control by working with the body’s natural hormonal signals. It features Amarasate®, a clinically studied extract of New Zealand bitter hops, delivered in a delayed-release capsule designed to reach the small intestine, where it activates bitter taste receptors. This triggers the release of key satiety hormones, including GLP-1, CCK, and PYY, which work together to significantly reduce hunger, cravings, and caloric intake. Fast-acting and plant-based, Calocurb® CLINICAL offers a targeted, science-driven approach to supporting healthy weight management.
Patients should use the Calocurb® CLINICAL Maintenance pack following the Starter Pack. As-needed administration is recommended only for those experienced with Calocurb® CLINICAL and knowledgeable of their individual response.
Key Benefits and Features:
| Serving Size: 1 Vegetarian Capsule | Amount/Serving |
| Amarasate extract (New Zealand Hops Flower Extract) | 250 mg |
Other Ingredients: Canola Oil (non-GMO and Glyphosate-free), Rosemary Leaf Extract, Vegetarian Capsule (Hypromellose).
Does Not Contain: Sugar, starch, yeast, wheat, gluten, soy, milk, eggs, shellfish, fish, peanuts, tree nuts, artificial colors, artificial flavors, or artificial preservatives.
Patients should continue on a dose of Calocurb® CLINICAL 250 mg twice daily, using the Maintenance Pack.
Take one 250 mg capsule, twice daily, one hour before a meal. Always take on an empty stomach with a minimum of 8 ounces of water.
Warning: This product is not intended for pregnant or nursing women or for persons under 18. Consult with your healthcare professional prior to use if you have or suspect a medical condition or are taking prescription drugs. Discontinue use and seek advice from a doctor if any adverse reactions occur.
Storage: Keep in a cool, dry place.
Successful weight management is now a global health concern as more than 43% of adults are categorized as overweight or obese. Long-term weight management requires lifestyle modification but often includes higher-force interventions such as pharmaceutical or surgical care. Pharmaceutical interventions are usually designed to reduce food intake by manipulating appetite; however, these interventions have long-term feasibility or safety concerns. Naturally derived compounds, with favorable safety profiles and the ability to powerfully suppress appetite and cravings, represent an appealing option for ongoing weight management.
Appetite regulation is orchestrated by a complex network of physical and chemical signals, with enteroendocrine hormones serving as some of the most powerful drivers of hunger and satiety. Under normal physiology, orexigenic hormones such as ghrelin rise during fasting and between meals, while anorexigenic hormones, including GLP-1, CCK, and PYY, are released after eating. Specialized enteroendocrine cells in the gastrointestinal tract release these hormones in a dose- and time-dependent manner in response to nutrient intake.
Bitter plant compounds have long been recognized for their role in modulating appetite. Historically, certain cultures intentionally consumed bitter plants to help manage hunger during extended travel or periods of limited food availability.5 These compounds stimulate bitter (TAS2R) receptors located throughout the gastrointestinal tract, triggering an enhanced anorexigenic hormone response (GLP-1, CCK, and PYY). Activation of these receptors by non-toxic bitter plant extracts can support optimal appetite regulation, providing a natural, targeted strategy for modern weight management.
In 2010, the New Zealand government funded a large grant to investigate the appetite suppressive effects of bitter plant compounds as a potential treatment option for weight management. After investigating over 1,000 different plant compounds in vitro, the researchers concluded that a native New Zealand hops extract produced the strongest TAS2R stimulation and consequential enhanced release of anorexigenic (GLP-1, CCK, and PYY) hormonal response, indicating the strongest appetite suppressant effect. The researchers named the extract Amarasate®, derived from Latin, meaning “bitter satiation.”
In 2019, the first clinical study on Amarasate® was conducted in a randomized, double-blind trial investigating its appetite suppressive effects during a 24-hour, water-only fast. Participants given Amarasate® or placebo at hours 16 and 20 were evaluated for hunger and satiety with a standard visual analog scale (VAS) every 30 minutes after capsule administration. Amarasate® participants reported an 80% reduction in hunger elevation scores compared to the placebo group. In a comparable water-fast study conducted in women, Amarasate® supplementation led to a 100% suppression of hunger elevation and a 120% reduction in food cravings relative to placebo.
A more expansive study of adult men sought to correlate the subjective reduction in hunger from the first study with anorexigenic biomarkers, specifically GLP-1, CCK, and PYY. The study also sought to investigate which was more efficacious, intragastric or intraduodenal delivery of Amarasate®. In the randomized, double-blind study, the subjects were given either a placebo, intraduodenal Amarasate® (delayed-release capsule), or intragastric Amarasate® (immediate-release capsule) one hour before an ad libitum meal and subsequent snack. Both Amarasate® delivery methods had significant elevations in GLP-1, CCK, and PYY; however, the intragastric capsule also had significantly more adverse events than the intraduodenal capsule, likely due to the high amount of TAS2R bitter receptors in the stomach. Intraduodenal delivery of Amarasate® resulted in 600% elevation from baseline of GLP-1 and CCK, and 50% elevation of PYY.
Amarasate® is a potent and effective appetite modulator, offering a targeted approach to supporting satiety and caloric control. It can be used independently or integrated into a comprehensive strategy for weight loss or maintenance. Calocurb® CLINICAL may be co-administered with weight-loss medications to help manage breakthrough hunger or used during medication tapering to support appetite control. Alternatively, Calocurb® CLINICAL can also be used as needed to support adherence to time-restricted eating or to help manage appetite and craving increases that may occur premenstrually.
Patients should use the Calocurb® CLINICAL Maintenance pack following the Starter Pack. As-needed administration is recommended only for those experienced with Calocurb® CLINICAL and knowledgeable of their individual response.
